Holen Sie sich die Stockscreener-App
22.26
0.13%
0.03
Handel nachbörslich:
22.26
Schlusskurs vom Vortag:
$22.23
Offen:
$22.22
24-Stunden-Volumen:
263.85K
Relative Volume:
0.94
Marktkapitalisierung:
$691.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-62.26M
KGV:
-9.6728
EPS:
-2.3013
Netto-Cashflow:
$-53.80M
1W Leistung:
+7.23%
1M Leistung:
+31.79%
6M Leistung:
+472.24%
1J Leistung:
+604.43%
1-Tages-Spanne:
$21.78
$22.83
1-Wochen-Bereich:
$20.28
$23.56
52-Wochen-Spanne:
$1.60
$23.56
Alto Neuroscience Inc Stock (ANRO) Company Profile
Firmenname
Alto Neuroscience Inc
Sektor
Branche
Telefon
773-255-5012
Adresse
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
22.26 | 690.60M | 0 | -62.26M | -53.80M | -2.3013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-11-17 | Eingeleitet | BTIG Research | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-23 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-09-03 | Eingeleitet | Wedbush | Outperform |
| 2024-02-27 | Eingeleitet | Jefferies | Buy |
| 2024-02-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-27 | Eingeleitet | Stifel | Buy |
| 2024-02-27 | Eingeleitet | TD Cowen | Outperform |
| 2024-02-27 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum - BioSpace
Alto Neuroscience (NYSE:ANRO) Trading 7.3% HigherWhat's Next? - MarketBeat
Alto Neuroscience Stock Pre-Market (-7.0%): Geopolitical Tensions Spark Risk-Off Move - Trefis
VSE Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday - Intellectia AI
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Market Review: What are Alto Neuroscience Incs earnings expectationsPortfolio Profit Report & Low Drawdown Momentum Ideas - baoquankhu1.vn
Fed Meeting: Is Alto Neuroscience Inc benefiting from interest rate changesDay Trade & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ANRO Stock Price, Quote & Chart | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Alto Neuroscience (NYSE:ANRO) Stock Price Down 7.2%What's Next? - MarketBeat
Alto Neuroscience Stock Quote, Share Price, News and Analysis - Longbridge
Alto Neuroscience (NASDAQ: ANRO) CEO has shares withheld for taxes - Stock Titan
Alto Neuroscience (ANRO) CFO reports 2,806-share tax withholding - Stock Titan
ANRO: ALTO-207 and ALTO-101 advance with biomarker-driven trials and improved formulations for mental health - TradingView
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week HighShould You Buy? - MarketBeat
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - Benzinga
ARMISTICE CAPITAL, LLC Reduces Stake in Alto Neuroscience Inc - GuruFocus
March Presentations to Spotlight Alto Neuroscience's Clinical Strategy - AD HOC NEWS
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - The Joplin Globe
Alto Neuroscience, Inc. (NYSE:ANRO) Slides in Biotech Indices - Kalkine Media
Alto Neuroscience (NYSE:ANRO) Trading Down 6.6%What's Next? - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading Up 10%Here's What Happened - MarketBeat
Vestal Point reports 8% stake in Alto Neuroscience (ANRO) - Stock Titan
ANRO: BTIG Analyst Maintains 'Buy' Rating, Raises Price Target t - GuruFocus
ANRO: BTIG Analyst Maintains 'Buy' Rating, Raises Price Target to $28 | ANRO Stock News - GuruFocus
K2 HealthVentures discloses 2.4% Alto Neuroscience (ANRO) stake via stock, warrants, debt - Stock Titan
Market Overview: Can Alto Neuroscience Inc expand into new marketsPortfolio Gains Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Alto Neuroscience completes enrollment in schizophrenia drug trial By Investing.com - Investing.com Australia
Alto Neuroscience completes enrollment in schizophrenia drug trial - Investing.com South Africa
Analysts Are Bullish on Top Healthcare Stocks: Grace Therapeutics (GRCE), Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia - BioSpace
What are Alto Neuroscience Inc.’s recent SEC filings showing2025 Earnings Impact & Capital Efficient Trading Techniques - mfd.ru
Is Alto Neuroscience Inc. stock attractive after correctionPortfolio Performance Summary & AI Enhanced Trading Alerts - mfd.ru
Alto Neuroscience (NYSE:ANRO) Trading 9.8% HigherShould You Buy? - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share Price - Yahoo Finance
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - BioSpace
Alto Neuroscience announces $75 million ATM offering - MSN
Aug Volume: Can Andretti Acquisition Corp. II Equity Warrant maintain its current growth rate2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Context Therapeutics (CNTX) and Connect Biopharma Holdings (CNTB) - The Globe and Mail
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Short Interest in Alto Neuroscience, Inc. (NYSE:ANRO) Drops By 21.0% - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analyst Calls: What chart patterns are forming on VNOPRNTrade Signal Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Alto Neuroscience receives patent for depression treatment method By Investing.com - Investing.com Nigeria
Alto Neuroscience issued patent for ALTO-207 - TipRanks
Alto Neuroscience Granted Patent for New Method of Treating Depression With ALTO-207 - marketscreener.com
Alto Neuroscience receives patent for depression treatment method - Investing.com
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression - Business Wire
Short Squeeze: Can Alto Neuroscience Inc stock deliver strong Q4 earningsPortfolio Gains Summary & Reliable Price Breakout Signals - Bộ Nội Vụ
Finanzdaten der Alto Neuroscience Inc-Aktie (ANRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):